High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo

Journal:
The Journal of Allergy and Clinical Immunology
Published:
DOI:
10.1016/j.jaci.2025.05.028
Affiliations:
6
Authors:
6
Go to article
Institutions Authors Share
University of Bern (UniBE), Switzerland
2.000000
 0.33
Bern University Hospital, Switzerland
2.000000
 0.33
Excellergy, United States of America (USA)
1.000000
 0.17
Stanford University, United States of America (USA)
1.000000
 0.17
Interested in Immunology?